TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23172028

Group type: EXPERIMENTAL
Intervention: Original manufacturer-supplied cuff
Number of subjects: 54

Group type: COMPARATOR
Intervention: Washable replacement cuff
Number of subjects: 54
Study: 21303934

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) delivered via videophones
Number of subjects: 42
Study: 18311597

Group type: EXPERIMENTAL
Intervention: Kaohsiung, Taiwan students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nanjing, China students
Number of subjects: 0
Study: 16782715

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 813
Study: 12622106

Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol combined with midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Target-controlled infusion of propofol combined with midazolam
Number of subjects: 40
Study: 10229290

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No identifiable source of exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation with HbA1c, BMI, and deprivation scores
Number of subjects: 0
Study: 8983891

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM (5‐fluorouracil 600 mg/m2/day i.v. on days 1, 8, 29 and 36, epirubicin 45 mg/m2/day i.v. on days 1 and 29, mitomycin C 10 mg/m2 i.v. on day 1, repeated every 56 days for 3 cycles)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM (specifically for histologic grade III tumors)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM
Number of subjects: 84
Study: 1753046

Group type: EXPERIMENTAL
Intervention: Nursing Home Care Unit (NHCU) teaching sessions
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control sessions in acute care wards
Number of subjects: 106
Study: 6751510

Group type: EXPERIMENTAL
Intervention: gentamicin-betamethasone ointment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: gentamicin alone
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo ointment
Number of subjects: 46
Study: 31690561

Group type: EXPERIMENTAL
Intervention: Stand alone VR (six week, internet based intervention with weekly online sessions and daily exercises)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Blended VR (same internet based intervention supplemented by face-to-face physiotherapy support)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Stand alone VR
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Blended VR
Number of subjects: 322

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 322
Study: 28652293

Group type: EXPERIMENTAL
Intervention: interface‐focused educational intervention
Number of subjects: 33
Study: 25545744

Group type: EXPERIMENTAL
Intervention: Green Tea (GT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Black Tea (BT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 113
Study: 23397347

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (7500 μg) once a week
Number of subjects: 581870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581870
Study: 21251187

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guidance for puncture in addition to fluoroscopy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Fluoroscopy-guided renal access
Number of subjects: 224
Study: 19809026

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Fe(III)-hydroxide sucrose (200 mg) on the third day of hypoxia
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Fe(III)-hydroxide sucrose (400 mg) after venesection
Number of subjects: 33

Group type: COMPARATOR
Intervention: Venesection of 2 L of blood (iron depletion)
Number of subjects: 33
Study: 17580441

Group type: EXPERIMENTAL
Intervention: Acupoint‐catgut‐embedding
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 80
Study: 15101309

Group type: EXPERIMENTAL
Intervention: Ferrule group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonferrule group
Number of subjects: 0
Study: 11470688

Group type: EXPERIMENTAL
Intervention: High-Dk RGP lenses for 12 months of 6-nights/week EW
Number of subjects: 201

Group type: COMPARATOR
Intervention: Medium-Dk RGP lenses for 12 months of 6-nights/week EW
Number of subjects: 201
Study: 11251357

Group type: EXPERIMENTAL
Intervention: Prolonged prophylaxis with low-molecular-weight heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of administering LMWH (including teaching self-administration and follow-up visit)
Number of subjects: 0
Study: 9503532

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID) administered for 3 weeks, 4 times a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Molsidomine (M) administered for 3 weeks, 4 times a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of efficacy after 3 weeks of regular intake
Number of subjects: 18
Study: 8458187

Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3757766

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30115593

Group type: EXPERIMENTAL
Intervention: Temozolomide (150-200 mg/m2, orally) monotherapy on days 1-5 every 4 weeks for a maximum of 12 cycles
Number of subjects: 155

Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg, intravenously) in combination with temozolomide (150-200 mg/m2, orally)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Temozolomide monotherapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Bevacizumab and temozolomide combination
Number of subjects: 155
Study: 27695978

Group type: EXPERIMENTAL
Intervention: Red spinach extract (RSE) 1000 mg dose; 90 mg nitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Red spinach extract (RSE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Red spinach extract (RSE) and Placebo (PBO)
Number of subjects: 15
Study: 23843470

Group type: EXPERIMENTAL
Intervention: HIT-6 questionnaire
Number of subjects: 490
Study: 23291073

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP regimen)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP regimen)
Number of subjects: 63
Study: 20055772

Group type: EXPERIMENTAL
Intervention: Antiparkinson drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study: 19057272

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally twice daily + Docetaxel 75 mg/m2 intravenously on a 21-day cycle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 20
Study: 16176006

Group type: EXPERIMENTAL
Intervention: Glycerol test during the period of onset
Number of subjects: 72

Group type: COMPARATOR
Intervention: Glycerol test during the period of intermission
Number of subjects: 72
Study: 12207638

Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel formulation (1200 mg three times daily) plus rifabutin (300 mg once daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rifabutin (300 mg once daily) alone
Number of subjects: 14
Study: 10335967

Group type: EXPERIMENTAL
Intervention: iodixanol 270 mg I/ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 50
Study: 8944373

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily (LAN30)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily (OME40)
Number of subjects: 211
Study: 2011924

Group type: EXPERIMENTAL
Intervention: Standard-dose alpha-IFN (3 MU/day i.m. for 6 months, then 3 MU three times/week for a further 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose alpha-IFN (1.5 MU/day with the same schedule and for the same period)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose alpha-IFN
Number of subjects: 24
Study: 29797695

Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg d‐1 for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (500 mg d‐1 for 4 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 44
Study: 27924138

Group type: EXPERIMENTAL
Intervention: MIPS (NO‐Shotgun®)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (isocaloric maltodextrin placebo)
Number of subjects: 8
Study: 24850540

Group type: EXPERIMENTAL
Intervention: Functional tasks exercise group (n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Active cognitive training group (n = 40)
Number of subjects: 83
Study: 22223077

Group type: EXPERIMENTAL
Intervention: Left anodal-right cathodal tDCS modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left cathodal-right anodal tDCS modulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 19949906

Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral component
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cobalt-chrome femoral component
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both components
Number of subjects: 100
Study: 18457473

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 16647506

Group type: EXPERIMENTAL
Intervention: Two doses of Simulect (20 mg intravenously per dose, one given 2 hours before transplantation and the second on day 4 posttransplant)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Single dose of Simulect (exact dosage not specified)
Number of subjects: 52
Study: 14653294

Group type: EXPERIMENTAL
Intervention: 330‐carbide bur
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 330 fine‐grit diamond bur
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 330 medium‐grit diamond bur
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (enamel margins)
Number of subjects: 90
Study: 10793015

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) three times daily for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo three times daily for 2 weeks
Number of subjects: 16
Study: 8640423

Group type: EXPERIMENTAL
Intervention: Individual Child and Parent Cognitive‐Behavioral Treatment (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family Therapy (FT)
Number of subjects: 0
Study: 1575250

Group type: EXPERIMENTAL
Intervention: Imipramine (up to 300 mg/day)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Phenelzine (up to 90 mg/day)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 2857087

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion (4-5 ng/kg/minute for 72 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 30
Study: 31392890

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D3
Number of subjects: 0
Study: 28077047

Group type: COMPARATOR
Intervention: Standard infusion (SI) of cefepime 2g IV every 8h with 30-min infusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of cefepime 2g IV every 8h with 3h infusion
Number of subjects: 63
Study: 26899475

Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Hopefulness
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Emotional regulation
Number of subjects: 790

Group type: COMPARATOR
Intervention: Enacted stigma
Number of subjects: 790
Study: 24449243

Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiotherapy (CRT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 147
Study: 22221937

Group type: EXPERIMENTAL
Intervention: 10% to 20% preemptive warfarin dose reduction
Number of subjects: 37

Group type: COMPARATOR
Intervention: Reactive warfarin dose adjustment
Number of subjects: 37
Study: 20187454

Group type: EXPERIMENTAL
Intervention: Traditional simple sacral laminectomies with resection of the cysts (group A, 25 cases)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CT‐guided percutaneous fibrin glue therapy of arachnoid cysts (group B, 30 cases)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 55
Study: 17512795

Group type: EXPERIMENTAL
Intervention: Long-term oxygen administration for more than 3 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Short-term oxygen administration for 2 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated OSAS patients
Number of subjects: 48
Study: 16138333

Group type: EXPERIMENTAL
Intervention: Short-course high-dose methylprednisolone (HDMP) at a daily dose of 30 mg/kg starting 4 days before consolidation therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Short-course high-dose methylprednisolone (HDMP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no HDMP)
Number of subjects: 34
Study: 12202418

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.8 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (0.8 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral misoprostol continued for an additional 7 days
Number of subjects: 34
Study: 10207682

Group type: EXPERIMENTAL
Intervention: Knee angular velocity of 60 degrees.s‐1
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee angular velocity of 180 degrees.s‐1
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee angular velocity of 120 degrees.s‐1
Number of subjects: 11
Study: 7791814

Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine (2.5 to 5 mg per kilogram of body weight per day) and methotrexate (at the maximal tolerated dose)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine and methotrexate
Number of subjects: 148
Study: 2350206

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 16
Study: 359085

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy without pyloroplasty
Number of subjects: 64
Study: 30531419

Group type: EXPERIMENTAL
Intervention: Compression socks (COMP, n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive control (CON, n = 6)
Number of subjects: 12
Study: 28683016

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PMR technique)
Number of subjects: 60
Study: 27004301

Group type: EXPERIMENTAL
Intervention: Vitamin D₂ (20,000 IU weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (15,000 IU weekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (D₂ or D₃)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vitamin D₂ vs Vitamin D₃
Number of subjects: 47
Study: 24195210

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment combined with semiconductor laser irradiation
Number of subjects: 30
Study: 22061038

Group type: EXPERIMENTAL
Intervention: PCP motivational interview + CATCH‐IT Internet program (MI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: PCP brief advice + CATCH‐IT Internet program (BA)
Number of subjects: 84
Study: 19560764

Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard cannulation technique (SCT)
Number of subjects: 188
Study: 17026508

Group type: EXPERIMENTAL
Intervention: Tension side
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Compression side
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control teeth
Number of subjects: 18
Study: 12594313

Group type: EXPERIMENTAL
Intervention: Experimental therapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin, alternating with ifosfamide and etoposide
Number of subjects: 518

Group type: COMPARATOR
Intervention: Standard therapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin
Number of subjects: 518
Study: 10225164

Group type: EXPERIMENTAL
Intervention: Study Group (SG) - received a list of seven questions before the preoperative interview.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control Group (CG) - did not receive any suggested questions.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (SG and CG)
Number of subjects: 125
Study: 9102242

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single joint puncture
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multiple puncture and intraarticular antibiotic therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Arthrotomy and drainage of the joint
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Arthrotomy from antero-lateral approach, suction drainage for 24-48 hours, systemic intravenous antibiotic therapy, abduction position of extremity in Frejka pillow and early physiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Radiographic results according to Hunk classification
Number of subjects: 75
Study: 1992877

Group type: EXPERIMENTAL
Intervention: Elevated ESR (greater than 30 mm/h) after therapy
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Early relapse
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: ESR patterns 4, 5, and 6
Number of subjects: 772

Group type: COMPARATOR
Intervention: Modern radiotherapy
Number of subjects: 772
Study: 6337624

Group type: EXPERIMENTAL
Intervention: Grating stimulation (CAM therapy)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Full-time occlusion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Grating stimulation
Number of subjects: 38
Study: 29769167

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Post-PCI bivalirudin infusion
Number of subjects: 7213
Study: 29578595

Group type: EXPERIMENTAL
Intervention: Moderate-intensity group (2 group sessions, laboratory report of baseline smoke exposure, 3 follow-up calls over 6 months)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Brief-intensity group (1 group session on tobacco-cessation resources)
Number of subjects: 203
Study: 26599371

Group type: EXPERIMENTAL
Intervention: Feedback on relatively good trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback on relatively poor trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness of feedback manipulation (aware group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unawareness of feedback manipulation (unaware group)
Number of subjects: 0
Study: 24481333

Group type: EXPERIMENTAL
Intervention: Matrix(2) polyglycolic/polylactic acid biopolymer‐modified coils
Number of subjects: 626

Group type: COMPARATOR
Intervention: Bare metal coils
Number of subjects: 626
Study: 22617130

Group type: EXPERIMENTAL
Intervention: S‐1+paclitaxel
Number of subjects: 83

Group type: COMPARATOR
Intervention: S‐1+cisplatin
Number of subjects: 83
Study: 19095215

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by axillary lymph node dissection (ALND)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Primary axillary lymph node dissection (ALND) after positive sentinel node biopsy
Number of subjects: 191
Study: 17239076

Group type: EXPERIMENTAL
Intervention: Group counselling program performed two days per week, each session lasting one hour.
Number of subjects: 62

Group type: COMPARATOR
Intervention: No counselling (control group).
Number of subjects: 62
Study: 16239941

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 114850

Group type: EXPERIMENTAL
Intervention: Journal articles
Number of subjects: 114850

Group type: EXPERIMENTAL
Intervention: Multicenter studies
Number of subjects: 114850

Group type: EXPERIMENTAL
Intervention: English language publications
Number of subjects: 114850

Group type: EXPERIMENTAL
Intervention: Core journals identified
Number of subjects: 114850
Study: 12139535

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 150 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral clonidine 150 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plain bupivacaine 15 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 45
Study: 10340983

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 36
Study: 7787819

Group type: EXPERIMENTAL
Intervention: Air pollution exposure (measured through outdoor air contaminants including nitrogen oxides and sulphur dioxide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms from upper and lower respiratory tract and general symptoms of ill health
Number of subjects: 0
Study: 2522919

Group type: EXPERIMENTAL
Intervention: Continuous infusion SR 2508 (etanidazole)
Number of subjects: 21
Study: 332100

Group type: EXPERIMENTAL
Intervention: Intravenous fructose treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 0
Study: 31937347

Group type: EXPERIMENTAL
Intervention: Ronopterin (48-hour intravenous infusion starting at 6 to 18 hours after injury)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (48-hour intravenous infusion starting at 6 to 18 hours after injury)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ronopterin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0